Download PDF
Dtsch Med Wochenschr 2004; 129(1/2): 31-35
DOI: 10.1055/s-2004-812659
Übersichten
Immunologie
© Georg Thieme Verlag Stuttgart · New York

Hitzeschockproteine, Immunkompetenz und Vakzinierung[1]

Heat shock proteins, immune competence and vaccinationV. Milani1 , M. Endres2 , M. C. Kuppner1 , R. D. Issels1 , 2 , E. Noessner2
  • 1Medizinische Klinik III, KKG Hyperthermie, Klinikum Großhadern, LMU-München
  • 2GSF-Institut für Molekulare Immunologie, München
Further Information

Publication History

eingereicht: 3.7.2003

akzeptiert: 15.9.2003

Publication Date:
02 January 2004 (online)

Also available at
    Permissions and Reprints

Hitzeschockproteine (HSP) sind hochkonservierte, zytoprotektive Proteine, die unter Zellstress überexprimiert werden. Die Erforschung ihrer immunologischen Eigenschaften hat sich in den letzten Jahren zu einer neuen und vielversprechenden Disziplin der Immunologie etabliert. Zahlreiche präklinische Arbeiten zeigen, dass HSP, wenn sie sich im extrazellulären Milieu befinden, das angeborene und das adaptive Immunsystem effizient stimulieren können. Derzeit laufen HSP-basierte Vakzinierungsansätze in klinischen Studien der Phase II und III, um das „Proof of principle” und die anti-tumorale Immunantwort in vivo nachzuweisen.

Die Hyperthermie-Behandlung von Tumoren hat neben dem direkten zytotoxischen Effekt auch eine indirekte immunmodulatorische Wirkung, indem die Expression von HSP induziert wird und durch die Hyperthermie-bedingte Nekrose auch HSP freigesetzt werden.

Ziel der aktuellen Forschung ist, neue Erkenntnisse über die durch Hyperthermie-Behandlung induzierte Immunantwort zu erhalten, sowie Änderungen in der Tumorphysiologie besser zu verstehen, um die Effektivität der Hyperthermiebehandlung und der HSP-basierten Vakzinierungen für Patienten mit fortgeschrittenen Tumoren zu verbessern.

1 Dieses Forschungsprojekt wird durch das SFB455-Projekt B9 und das Krebshilfe-Projekt 7023011-Is/2 gefördert.

Literatur

  • 1 Akira S. Mammalian Toll-like receptors.  Curr Opin Immunol. 2003;  15 5-11
    Google Scholar
  • 2 Atanackovic D, Nierhaus A, Neumeier M, Hossfeld D K, Hegewisch-Becker S. 41.8 degrees C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases.  Cancer Immunol Immunother. 2002;  51 603-613
    Google Scholar
  • 3 Asea A, Kraeft S K, Kurt-Jones E A. et al . HSP70 stimulates cytokine production through a CD14 dependent pathway, demonstrating a dual role as a chaperone and cytokine.  Nat Med. 2000;  6 435-442
    Google Scholar
  • 4 Asea A, Rehli M, Kabingu E. et al . Novel signal transduction pathway utilized by extracellular HSP70: role of TLR2 and TLR4.  J Biol Chem. 2002;  277 15028-15034
    Google Scholar
  • 5 Banchereau J, Steinmann R M. Dendritic cells and the control of immunity.  Nature. 1999;  392 245-252
    Google Scholar
  • 6 Basu S, Binder R J, Ramalingam T, Srivastava P K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.  Immunity. 2001;  14 303-313
    Google Scholar
  • 7 Bausinger H, Lipsker D, Ziylan U. et al . Endotoxin-free heat-shock protein 70 fails to induce APC activation.  Eur J Immunol. 2002;  32 3708-3713
    Google Scholar
  • 8 Becker T, Hartl F U, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes.  J Cell Biol. 2002;  158 1277-1285
    Google Scholar
  • 9 Belli F, Testori A, Rivoltini L. et al . Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.  J Clin Oncol. 2002;  20 4169-4180
    Google Scholar
  • 10 Bethke K, Staib F, Distler M. et al . Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60.  J Immunol. 2002;  169 6141-6148
    Google Scholar
  • 11 Binder R J, Blachere N E, Srivastava P K. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules.  J Biol Chem. 2001;  276 17 163-17 171
    Google Scholar
  • 12 Breloer M, More S, Dorner B, Fleischer B, von Bonin A. Hitzeschockproteine als Gefahrensignale: HSP60 verstärkt die antigenspezifische Aktivierung primärer T-Zellen.  Immunologie Aktuell. 2001;  2 64-66
    Google Scholar
  • 13 Buchner J, Walter S. Molecular chaperones-Cellular machines for protein folding.  Angew Chem Int Ed. 2002;  41 1098-1113
    Google Scholar
  • 14 Bukau B, Horwich A L. The HSP70 and HSP60 chaperone machines.  Cell. 1998;  92 351-366
    Google Scholar
  • 15 Castelli C, Ciupitu A M, Rini F. et al . Human heat shock 70 peptide complexes specifically activate antimelanoma T cells.  Cancer Res. 2001;  61 222-227
    Google Scholar
  • 16 Chen W, Syldath U, Bellmann K, Burkart V, Kolb H. Human 60 kDa heat shock protein. A danger signal to the innate immune response.  J Immunol. 1999;  162 3212-3219
    Google Scholar
  • 17 Ciupitu A M, Petersson M, Odonnell C L. et al . Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes.  J Exp Med. 1998;  187 685-691
    Google Scholar
  • 18 Delneste Y, Magistrelli G, Gauchat J F. et al . Involvement of LOX-1 in Dendritic Cell-Mediated Antigen Cross-Presentation.  Immunitiy. 2002;  17 352-362
    Google Scholar
  • 19 Falk M, Issels R D. Hyperthermia in oncology.  Int J Hyperthermia. 2001;  17 1-18
    Google Scholar
  • 20 Flohe S B, Bruggemann J, Lendemans S. et al . Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype.  J Immunol. 2003;  170 2340-2348
    Google Scholar
  • 21 Fuller J, Issels R, Slosman D, Guillet J G, Soussi T, Polla B S. Cancer and the heat shock response.  Eur J Cancer. 1994;  12 1884-1891
    Google Scholar
  • 22 Gehrmann M, Pfister K, Hutzler P, Gastpar R, Margulis B, Multhoff G. Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels.  Biol Chem. 2002;  383 1715-1725
    Google Scholar
  • 23 Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis J J, Srivastava P K. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparation: a pilot study.  Int J Cancer. 2000;  88 232-238
    Google Scholar
  • 24 Janeway  C A Jr., Medzhitov R. Innate immune recognition.  Annu Rev Immunol. 2002;  20 197-216
    Google Scholar
  • 25 Keilholz U, Weber J, Finke J H. et al . Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.  J Immunother. 2002;  25 97-138
    Google Scholar
  • 26 Kuppner M, Gastpar R, Gelwer S. et al . The role of heat shock protein (HSP70) in dendritic cell maturation: HSP70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocytes precursors.  Eur J Immunol. 2001;  31 1602-1609
    Google Scholar
  • 27 Matzinger P. Tolerance, danger, and the extended family.  Annu Rev Immunol. 1994;  12 991-945
    Google Scholar
  • 28 Medzhitov R, Preston-Hurlburt P, Janeway C A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.  Nature. 1997;  388 394-397
    Google Scholar
  • 29 Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile R G. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock proteins expression.  Nat Med. 1998;  4 581-587
    Google Scholar
  • 30 Milani V, Noessner E, Ghose S. et al . Heat shock protein 70: role in antigen presentation and immune stimulation.  Int J Hyperthermia. 2002;  18 563-575
    Google Scholar
  • 31 Milarski K L, Morimoto R I. Expression of human HSP70 during the synthetic phase of the cell cycle.  Proc Natl Acad Sci USA. 1986;  83 9517-9521 SE>
    Google Scholar
  • 32 Multhoff G. Activation of natural killer cells by heat shock protein 70.  Int J Hyperthermia. 2002;  18 576-585
    Google Scholar
  • 33 Multhoff G, Botzler C, Jennen L, Schmidt J, Ellwart J, Issels R. Heat shock protein 72 on tumour cells: a recognition structure for natural killer cells.  J Immunol. 1997;  158 4341-4350
    Google Scholar
  • 34 Noessner E, Gastpar R, Milani V. et al . Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells.  J Immunol. 2002;  169 5424-5432
    Google Scholar
  • 35 Parmiani G, Castelli C, Dalerba P. et al . Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?.  J Natl Cancer Inst. 2002;  94 805-818
    Google Scholar
  • 36 Singh-Jasuja H, Hilf N, Arnold-Schild D, Schild H. The role of heat shock proteins and their receptors in the activation of the immune system.  Biol Chem. 2001;  382 629-636
    Google Scholar
  • 37 Singh-Jasuja H, Toes R E, Spee P. et al . Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis.  J Exp Med. 2000;  191 1965-1974
    Google Scholar
  • 38 Singh-Jasuja H, Scherer H U, Hilf N, Arnold-Schild D, Rammensee H G, Toes R EM, Schild A. The heat shock protein gp96 induces maturation of dendritic cells and down regulation of its receptor.  Eur J Immunol. 2000;  30 2211-2215
    Google Scholar
  • 39 Somersan S, Larsson M, Fonteneau J, Basu S, Srivastava P, Bhardway N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells.  J Immunol. 2001;  167 4844-4852
    Google Scholar
  • 40 Srivastava P K. Immunotherapy of human cancer: lessons from mice.  Nature Immunology. 2000;  1 363-366
    Google Scholar
  • 41 Srivastava P K, DeLeo A B, Old L J. Tumor rejection antigens of chemically induced sarcomas in inbred mice.  Proc Natl Acad Sci USA. 1986;  83 3407-3411
    Google Scholar
  • 42 Srivastava P, Menoret A, Basu S, Binder R, McQuade K. Heat shock protein come of age: primitive functions acquire new roles in an adaptive world.  Immunity. 1998;  8 657-665
    Google Scholar
  • 43 Srivastava P K, Udono H. Heat shock protein-peptide complexes in cancer immunotherapy.  Curr Opin Immunol. 1994;  6 728-732
    Google Scholar
  • 44 Stewart J R, Gibbs F A. Hyperthermia in the treatment of cancer. Perspectives on its promise and its problems.  Cancer. 1984;  54 2823-2830
    Google Scholar
  • 45 Udono H, Srivastava P K. Heat shock protein 70-associated peptides elicit specific cancer immunity.  J Exp Med. 1993;  178 1391-96
    Google Scholar
  • 46 Udono H, Srivastava P K. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, HSP90 and HSP70.  J Immunol. 1994;  152 5398-5403
    Google Scholar
  • 47 Vabulas R M, Ahmad-Nejad P, da Costa C. et al . Endocytosed HSP60 s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells.  J Biol Chem. 2001;  276 31 332-31 339
    Google Scholar
  • 48 Vabulas R M, Ahmad-Nejad P, Ghose S, Kirschning C J, Issels R D, Wagner H. HSP70 as endogenous stimulus of Toll/interleukin-1 receptor signal pathway.  J Biol Chem. 2002;  277 15 107-15 112
    Google Scholar
  • 49 Vabulas R M, Braedel S, Hilf N. et al . The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway.  J Biol Chem. 2002;  277 20 847-20 853
    Google Scholar
  • 50 Vabulas R M, Wagner H, Schild H. Heat shock proteins as Ligands for Toll-like receptors.  Curr Top Microbiol Immunol. 2002;  270 169-184
    Google Scholar
  • 51 Wang X Y, Kazim L, Repasky E, Subjeck J. Characterization of heat shock protein 110 and glucose-regulated 170 as cancer vaccine and the effect of fever-range hyperthermia on vaccine activity.  J Immunol. 2001;  165 490-497
    Google Scholar
  • 52 Wells A D, Malkovsky M. Heat shock proteins, tumour immunogenicity and antigen presentation: an integrated view.  Immunol Today. 2000;  21 129-132
    Google Scholar

1 Dieses Forschungsprojekt wird durch das SFB455-Projekt B9 und das Krebshilfe-Projekt 7023011-Is/2 gefördert.

Valeria Milani

KKG Hyperthermie, Medizinische Klinik III, Klinikum Großhadern

Marchioninistraße 15

81377 München

Phone: 089/7099403

Fax: 089/7099450

Email: milani@gsf.de

      >